Skip to main navigation
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications & Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Stories
    • Patient Stories
    • Disease Focus
      • Overview
      • Transthyretin Amyloidosis
      • Hereditary Angioedema
      • Alpha-1 Antitrypsin Deficiency
      • Hodgkin Lymphoma
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Who We Are
    • Core Values
    • Leadership
    • Partners
    • Intellia’s Journey
  • Our Science
    • What is CRISPR?
    • CRISPR Videos
    • Full-Spectrum Approach
    • Scientific Publications &
      Presentations
    • Glossary
  • Programs & Pipelines
    • Pipeline
    • Clinical Trials
  • Patient Focus
    • Patient Stories
    • Disease Focus
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications &
      Presentations
    • Corporate Deck
    • Events &
      Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

Investors & Media

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Stock Information

  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Jun 05, 2023
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
Read More
Events & Presentations
Jun 12, 2023 8:00 AM EDT
Intellia Therapeutics Call to Discuss Interim Clinical Data of NTLA-2002
Add to Outlook
Add to Google Calendar
Click Here for Webcast
Jun 14, 2023 9:00 AM EDT
Intellia Therapeutics 2023 Annual Meeting of Shareholders

Location

Virtual meeting via internet
Add to Outlook
Add to Google Calendar
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2023

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.